{"title":"A Single-Center, Retrospective Comparison of Non-Pre-emptive with Pre-emptive Renal Transplantations.","authors":"Terra M Hill, Lauren T Kerivan, Diego R Mazzotti","doi":"10.17161/kjm.vol18.23625","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>End-stage renal disease (ESRD) requires renal replacement therapy, either through pre-emptive transplantation (PET) or non-pre-emptive transplantation (non-PET). PET is associated with improved patient and allograft survival compared to non-PET; however, only 2.5% of patients in the United States undergo PET. The authors of this study report on mortality and allograft rejection rates in patients undergoing PET versus non-PET.</p><p><strong>Methods: </strong>This single-center, retrospective study compared posttransplant complications between PET and non-PET in adults with ESRD. De-identified electronic health record data from 2017 to 2022 were analyzed. Odds ratios (ORs) for one-year post-transplant mortality and allograft rejection were calculated using unadjusted multivariate logistic regression (Model 1), adjusted for age and sex (Model 2), and further adjusted for comorbidities (Model 3).</p><p><strong>Results: </strong>A total of 787 patients with ESRD underwent kidney transplantation: 14% underwent non-PET and 86% underwent PET. Compared to PET, the ORs for one-year post-transplant mortality with non-PET were:Model 1: OR 1.76 (95% CI, 0.64-4.85; p = 0.27)Model 2: OR 2.02 (95% CI, 0.71-5.71; p = 0.19)Model 3: OR 1.86 (95% CI, 0.64-5.39; p = 0.24)For one-year allograft rejection, the ORs for non-PET versus PET were:Model 1: OR 1.63 (95% CI, 0.85-3.10; p = 0.13)Model 2: OR 1.61 (95% CI, 0.84-3.06; p = 0.15)Model 3: OR 1.60 (95% CI, 0.82-3.10; p = 0.16).</p><p><strong>Conclusions: </strong>This single-center study found no statistically significant differences in one-year mortality or allograft rejection between patients undergoing PET and non-PET.</p>","PeriodicalId":94121,"journal":{"name":"Kansas journal of medicine","volume":"18 4","pages":"86-88"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12370307/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kansas journal of medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17161/kjm.vol18.23625","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: End-stage renal disease (ESRD) requires renal replacement therapy, either through pre-emptive transplantation (PET) or non-pre-emptive transplantation (non-PET). PET is associated with improved patient and allograft survival compared to non-PET; however, only 2.5% of patients in the United States undergo PET. The authors of this study report on mortality and allograft rejection rates in patients undergoing PET versus non-PET.
Methods: This single-center, retrospective study compared posttransplant complications between PET and non-PET in adults with ESRD. De-identified electronic health record data from 2017 to 2022 were analyzed. Odds ratios (ORs) for one-year post-transplant mortality and allograft rejection were calculated using unadjusted multivariate logistic regression (Model 1), adjusted for age and sex (Model 2), and further adjusted for comorbidities (Model 3).
Results: A total of 787 patients with ESRD underwent kidney transplantation: 14% underwent non-PET and 86% underwent PET. Compared to PET, the ORs for one-year post-transplant mortality with non-PET were:Model 1: OR 1.76 (95% CI, 0.64-4.85; p = 0.27)Model 2: OR 2.02 (95% CI, 0.71-5.71; p = 0.19)Model 3: OR 1.86 (95% CI, 0.64-5.39; p = 0.24)For one-year allograft rejection, the ORs for non-PET versus PET were:Model 1: OR 1.63 (95% CI, 0.85-3.10; p = 0.13)Model 2: OR 1.61 (95% CI, 0.84-3.06; p = 0.15)Model 3: OR 1.60 (95% CI, 0.82-3.10; p = 0.16).
Conclusions: This single-center study found no statistically significant differences in one-year mortality or allograft rejection between patients undergoing PET and non-PET.